Do valsartan and losartan have the same effects in the treatment of coronary artery disease?

Circulation Journal

Volumn 71, Issue 1, 2007, Pages 32-38

  Iwata, Atsushi ^a   Miura, Shin Ichiro ^a   Imaizumi, Satoshi ^a   Kiya, Yoshihiro ^a   Nishikawa, Hiroaki ^a   Zhang, Bo ^a   Shimomura, Hideki ^b   Kumagai, Koichiro ^a   Matsuo, Kunihiro ^a   Shirai, Kazuyuki ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b Fukuoka Tokusyukai Hospital   (Japan)

Author keywords

Adhesion molecules; Angiotensin II type 1 receptor blockers; Class effects; Coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LOSARTAN; TICLOPIDINE; VALSARTAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN EXPRESSION; REVASCULARIZATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; CORONARY STENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; L-SELECTIN; LOSARTAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TETRAZOLES; VALINE;

EID: 33846016634     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.32     Document Type: Article

References (31)

1. De Gasparo M, Catt K, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII: The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
2. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006; 70: 995-1000.
3. Inamoto S, Hayashi T, Tazawa N, Mori T, Yamashita C, Nakano D, et al. Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. Circ J 2006; 70: 787-792.
4. Picca M, Agozzino F, Pelosi G. Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension. Adv Ther 2004; 21: 76-86.
5. Matsuda H, Hayashi K, Homma K, Yoshioka K, Kanda T, Takamatsu I, et al. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease. Hypertens Res 2003; 26: 875-880.
6. Awad AS, Webb RL, Carey RM, Siragy HM. Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. J Hypertens 2004; 22: 1571-1577.
7. Koh KK, Han SH, Chung WJ, Ahn JY, Jin DK, Kim HS, et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 2004; 93: 1432-1435, A10.
8. Pantev E, Stenman E, Wackenfors A, Edvinsson L, Malmsjo M. Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries. Eur J Heart Fail 2002; 4: 699-705.
9. Pitt S, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm JA, et al. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: The losartan heart failure survival study: ELITE II. Lancet 2000; 355: 15827.
10. Cohn J, Tognoni G, Glazer R, Sporman D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999; 5: 15560.
11. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-766.
12. Nakamura T, Fujii S, Hoshino J, Saito Y, Mizuno H, Saito Y, et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28: 937-943.
13. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ando N, Ohta S, et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005; 28: 865-870.
14. Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res 2003; 26: 937-943.
15. Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: A current perspective. Curr Hypertens Rev 2005; 1: 115-121.
16. Peters S, Gotting B, Trummel M, Rust H, Brattstrom A. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The VAL-PREST trial. J Invasive Cardiol 2001; 13: 93-97.
17. Kawamura A, Miura S, Murayama T, Iwata A, Nishikawa H, Matsuo Y, et al. Changes in the expression of leukocyte adhesion molecules throughout the acute phase of myocardial infarction. J Atheroscler Thromb 2004; 11: 29-34.
18. Kawamura A, Miura S, Fujino M, Nishikawa H, Matsuo Y, Tanigawa H, et al. CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease. Circ J 2003; 67: 851-854.
19. Shirai K, Lansky AJ, Mintz GS, Costantini CO, Fahy M, Mehran R, et al. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. Am J Cardiol 2003; 92: 1409-1413.
20. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am. Coll Cardiol 2001; 38: 2006-2012.
21. Makuuchi H, Furuse A, Endo M, Nakamura H, Daida H, Watanabe M, et al. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. Circ J 2005; 69: 636-643.
22. Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L, et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999; 10: 730-737.
23. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6: 499-500.
24. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-1601.
25. Kawamura A, Miura S, Murayama T, Iwata A, Zhang B, Nishikawa H, et al. Increased expression of monocyte CD11a and ICAM-1 in patients with initial atherosclerotic coronary stenosis. Circ J 2004; 68: 6-10.
26. Kawamura A, Miura S, Fujino M, Nishikawa H, Matsuo Y, Tanigawa H, et al. CXCR3 chemokine receptor: Plasma IP10 interaction in patients with coronary artery disease. Circ J 2003; 67: 851-854.
27. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-1652.
28. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004; 44: 335-339.
29. Grafe M, Auch-Schwelk W, Zakrzewicz A, Regitz-Zagrosek V, Bartsch P, Graf K, et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997; 81: 804-811.
30. Usui M, Egashira K, Tomita H, Koyanagi M, Katoh M, Shimokawa H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-310.
31. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385-392.